Wellington Partners is among the most successful pan-European Venture Capital firms. With more than € 800 million under management, we invest in start-up companies throughout Europe that have the potential to become global leaders. Going forward we plan to further expand our investment activities in life sciences, an area where we have a leading position in the German-speaking countries and beyond.
Since 1998, Wellington Partners has invested in approx. 40 life science companies, including publicly listed firms such as 4SC, Actelion (acquired by Johnson&Johnson), Evolva, Genkyotex, Noemalife, Oxford Immunotec, Supersonic Imagine and Wavelight (acquired by Alcon), as well as privately held companies such as Atopix (acquired by Chiesi), AyoxxA, Definiens (acquired by Medimmune/AstraZeneca), EndoStim, Grandis (acquired by Novartis), G-Therapeutics, immatics, invendo medical, iOmx, Middle Peak Medical (acquired by Symetis/Boston Scientific), mtm laboratories (acquired by Roche), Neuway Pharma, Perfect Vision (acquired by Bausch&Lomb), Quanta Dialysis Technologies, Rigontec, Sapiens (acquired by Medtronic), Sensimed, Symetis (acquired by Boston Scientific), Themis and UroMems.
T: +49 89 219941-20
Fax: +49 89 219941-7720